


Vision & Strategies




Combating diseases and strengthening global competitiveness
by leading cutting-edge regenerative medicine (RM) technology

범부처 재생의료
기술개발사업단


Korean Fund for Regenerative Medicine

Performance Goals

Goals
To develop RM treatment through development of basic technology and clinical translation



- Researcher-centered**
 - Establish a researcher-oriented R&D**
 - Create a research environment using faithful null results (FNR) and FNR database
 - Identify domestic R&D personnel, discover and nurture talents for cutting-edge regenerative medicine
- Patient-centered**
 - Realize patient-centered R&D**
 - Establish ties with biobanks and T2B businesses (preclinical evaluation centers) to ensure clinical validity
 - Operate a multi-directional communication system from the early stages of technological development to enhance the people's (patients, guardians, and general public) understanding of science
- Market-centered**
 - Promote market-centered R&D**
 - Support commercialization and economic feasibility from the initial stage of R&D
 - Help researchers surpass the death valley and provide practical support for entering a new market
 - Establish a cooperative system with regulatory authorities and advanced countries to secure safety and effectiveness
- Global-centered**
 - Expand world-leading R&D**
 - Promote domestic core technologies by analyzing the gaps between the advanced global technologies
 - Establish a preemptive response system for global development trends and regulations
 - Establish a collaborative research system with outstanding global universities, research institutes and private enterprises and secure funding




KFRM Korean Fund for Regenerative Medicine
17F, 110 Huam-ro, Jung-gu, Seoul
T +82-2-6263-3060 F +82-2-6263-3080 H www.kfrm.org




Initiatives Coordinate roles and responsibilities for effective program operation and establish a cooperative system with the ministries and coordinating agencies




Roles Support project planning, management, evaluation, and commercialization; establish research network and promote technology transfer; reinforce clinical translation; analyze and utilize project outcomes, etc.




R&D Lifecycle Management



Commercialization



Project



Program Details 1 Development of basic technology in regenerative medicine (TRL 1-3)

| Category | Details |
|--|---|
| Future RM basic technology | <ul style="list-style-type: none"> Purpose: To develop promising source technologies including convergence of biocompatible materials, in vivo cell transformation, and biomaterial-cell complex Duration: 3+2 years(2-staged) Target technologies: <ol style="list-style-type: none"> (1) Artificial cell tissues and xenogeneic organs development technology (2) Bio-reprogramming treatment technology (3) Biocompatible enhancement technology |
| Next generation candidate treatment technology | <ul style="list-style-type: none"> Purpose: To develop basic RM technology including cell differentiation/maintenance/efficiency improvement technology, organoids, and cell activation technology Duration: 3+2 years(2-staged), 3 years Target technologies: <ol style="list-style-type: none"> (1) Diversification and advancement of the cell differentiation technology (2) Technology for securing multicellular therapies (3) Endogenous stem cell activation technology |

Detailed Project 2 Development of translational technology in regenerative medicine (TRL 3-5)

| Category | Details |
|--|--|
| Next generation regenerative medicine applied technology (Technological convergence) | <ul style="list-style-type: none"> Purpose: To develop applied RM treatment and technology for verification purpose Duration: 3 years Target technologies: <ol style="list-style-type: none"> (1) Cell-based disease model technology (2) Cell-based drug development application technology (3) Organoid advancement and utilization technology |
| RM treatment technology (Technology advancement) | <ul style="list-style-type: none"> Purpose: To accelerate disease-targeting non-clinical RM treatment and technology to clinical stage Duration: 3+1 years(2-staged), 2 years Target disorders: <ol style="list-style-type: none"> (1) Musculoskeletal disorders (2) Nervous system disorders (3) Circulatory and respiratory disorders (4) Endocrine system disorders (5) Digestive system disorders (6) Other incurable disorders |

Detailed Project 3 Development of RM treatment and technology (TRL 6-7)

| Category | Details |
|--------------------------------|---|
| Sponsor Initiated Trials (SIT) | <ul style="list-style-type: none"> Purpose: To complete phase 2 clinical trial of disease-targeting RM treatment through MFDS IND approval Duration: 3 years Target disorders: <ol style="list-style-type: none"> (1) Musculoskeletal disorders (2) Nervous system disorders (3) Circulatory and respiratory disorders (4) Endocrine system disorders (5) Digestive system disorders (6) Other incurable disorders |